A securities class action lawsuit has been filed against Boston Scientific Corporation and certain officers, alleging violations of federal securities laws. The suit seeks damages on behalf of investors who bought or acquired the company’s securities between July 23, 2025 and February 3, 2026, claiming the company made materially false or misleading statements about the sustainability of projected 2025 growth, particularly in its U.S. electrophysiology segment, amid adverse trends and competitive, regulatory, and reimbursement pressures. Investors have until May 4, 2026 to seek appointment as lead plaintiff.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Boston Scientific Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603081200PRIMZONEFULLFEED9667556) on March 08, 2026, and is solely responsible for the information contained therein.
Comments